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To the Editor: Kidney transplantation improves sur-
vival and quality of life for patients with end-stage
renal disease. Lifelong immunosuppressive therapy
(IST) is required for kidney transplant (graft) survival,
at an average cost of >$20,000 per year.1 More than
10% of graft failure cases are attributed to IST non-
adherence.1 Under current US policy, Medicare IST
coverage is limited to 3 years after transplantation for
nondisabled recipients <65 years of age. Transplant
survival rates in the United States are lower than those
in developed nations that provide lifelong government-
funded IST.2 Patients with lifelong Medicare coverage
have substantially better >3-year outcomes than those
whose Medicare is limited to 3 years after trans-
plantation,2 and 51% of surveyed adult US transplant
centers reported deaths or graft failures due to cost-
related IST nonadherence.3 Advocates for legislation
to increase the duration of Medicare IST coverage
contend that this would likely improve IST adher-
ence.1,2 However, IST adherence has not been reported
in a cohort of US transplant recipients who receive
lifelong IST at no out-of-pocket cost. We studied IST
adherence rates in adult US Military Healthcare System
beneﬁciaries, who receive free lifelong IST after
transplantation.
This study was approved by Walter Reed National
Military Medical Center’s institutional review board.
Informed consent was obtained from adult ($18 years
of age) kidney transplant recipients seen in the Walter
Reed National Military Medical Center nephrology or
organ transplant clinics. Demographic and clinical
characteristics were ascertained by an electronic med-
ical record review. Patients were recruited consecu-
tively and were administered the Immunosuppressive
Therapy Adherence Scale (ITAS) and Beck Depression
Inventory-II (BDI-II). The ITAS is a questionnaire that
consists of 4 questions measuring IST nonadherence,
each scored by percentage of nonadherence (0 points
for >50% of the time, 1 point for 21%–50% of theKidney International Reports (2016) -, -–-time, 2 points for 1%–20% of the time, 3 points for 0%
of the time).4 ITAS scores range from 0 (score of 0 for
each question) to 12 (score of 3 for each of the 4
questions). Subjects with ITAS scores of 12/12 were
considered to have perfect adherence,5 and were
compared with subjects with ITAS scores of #11/12.
The BDI-II is a self-report instrument that contains 21
items. BDI-II scores range from 0 to 63, with higher
scores indicating the presence and severity of
depressed mood.6
Univariate analyses were performed with c2 testing
for categorical variables (Fisher exact test used for vi-
olations of Cochran’s assumptions) and Student’s t-test
for continuous variables. To assess whether the BDI-II
score is independently associated with the likelihood of
perfect versus not perfect adherence, we performed
exact logistic regression, adjusting for date of trans-
plant, sex, race, and age (STATA 13 SE; StataCorp,
College Station, TX).
Of 40 enrolled subjects, 39 (98%) completed the
ITAS. A total of 37 (95%) subjects reported ITAS
scores of $10, with 27 subjects (69%) reporting
perfect adherence. Demographic, socioeconomic, and
clinical data for subjects with perfect and not perfect
adherence are listed in Table 1. There were no sta-
tistically signiﬁcant demographic or socioeconomic
differences between the 2 groups. Donor-speciﬁc
antibody was positive in 3 of 24 (13%) tested sub-
jects with perfect adherence, compared with 6 of 9
(67%) with not perfect adherence, a signiﬁcant dif-
ference (P ¼ 0.005) (Figure 1). There were otherwise
no signiﬁcant differences in clinical indicators be-
tween the 2 groups. Perfectly adherent subjects had
signiﬁcantly lower mean BDI-II scores (6.7  7.2 vs.
13.6  8.8; P ¼ 0.01), and on exact multivariable
logistic regression, a 5-point BDI-II score increase was
associated with a signiﬁcantly lower likelihood of
perfect adherence (adjusted odds ratio, 0.61; 95%
conﬁdence interval, 0.32–0.98).
To our knowledge, this is the ﬁrst report of IST
adherence in US transplant recipients who receive
lifelong IST at no cost, regardless of time since
transplant, age, or disability status. Subjects in our
study reported high levels of adherence, irrespective
of demographic or socioeconomic factors, in contrast
to prior studies where non-white race7,8 and low in-
come8 were associated with nonadherence. Less
adherent subjects had higher BDI scores, and modest
increases in BDI score associated signiﬁcantly with
a lower likelihood of perfect adherence. Subjects
with less than perfect adherence on the ITAS were1
Table 1. Demographic and clinical characteristics of study subjects,
and ITAS and BDI-II results
Variables
Perfect
adherence
(ITAS 12/12)
(n [ 27)
Not perfect
adherence
(ITAS £ 11/12)
(n [ 12) P-value
Age at the time of study (yr) 51  16 56  12 0.3
Gender, n (%)
Male 18 (67) 4 (33) 0.08
Female 9 (33) 8 (67)
Race, n (%) 0.8
White 13 (48) 4 (33)
Black 9 (33) 5 (42)
Asian 3 (11) 3 (25)
Hispanic 2 (7) 0
Age (yr) at transplant 49.81  14.16 51.58  11.20 0.7
Time since transplant, n (%)
<3 yr 18 (67) 5 (42) 0.2
>3 yr 9 (3) 7 (58)
History of prior transplant, n (%)
Yes 4 (15) 0 (0) 0.3
No 23 (85) 12 (100)
Type of transplant, n (%)
Deceased donor 18 (67) 11 (92) 0.1
Living donor 9 (33) 1 (8)
Prior history of rejection, n (%)
Yes 2 (7) 4 (33) 0.06
No 25 (93) 8 (67)
Donor-speciﬁc antibody at the time
of survey
Positive 3 (11) 6 (50) 0.005
Negative 21 (78) 3 (25)
Unknown 3 (11) 3 (25)
Serum Cr at the time of survey
(mg/dl)
1.90  1.51 1.43  0.42 0.1
Spot urine protein/Cr ratio at the time
of survey
0.65  1.60 0.53  0.76 0.8
Education level, n (%)
$College degree 13 (48) 5 (42) 0.7
<College degree 12 (45) 6 (50)
Unknown 2 (7) 1 (8)
Marital status, n (%)
Married 20 (74) 8 (67) 0.7
Unmarried 7 (26) 4 (33)
Annual household income, n (%)
>$75,000 14 (52) 7 (58) 0.9
#$75,000 9 (33) 4 (33)
Unreported 4 (15) 1 (8)
ITAS score 12  0.00 10.42  1.00 <0.001
BDI-II score 6.7  7.17 13.58  8.76 0.01
Data are n (%) or mean  SD.
BDI-II, Beck Depression Inventory-II; ITAS, Immunosuppressive Therapy Adherence
Scale.
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Figure 1. Results of donor-speciﬁc antibody testing in subjects with
and without perfect adherence.
RESEARCH LETTERsigniﬁcantly more likely to have positive donor-
speciﬁc antibody, emphasizing the clinical relevance
of modest degrees of nonadherence. Limitations to our
study include the small sample size and cross-
sectional design. An alternative explanation for the
association between depression and nonadherence is
that the use of self-reporting to quantify adherence2may have led to a positive response bias whereby
subjects overestimated their IST adherence, which
may have been present to a lesser degree in patients
with depressed mood. Therefore, the inverse associ-
ation between the BDI score and self-reported
adherence should be interpreted with caution.
Strengths include detailed characterization of the co-
hort’s broad demographic, socioeconomic, and clinical
characteristics. Our results support the provision of a
large, prospective, controlled study to investigate the
effect of providing long-term IST at no cost to US
renal transplant recipients, and highlight the impor-
tance of identifying and treating depression after
kidney transplantation.
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